Provided by Tiger Fintech (Singapore) Pte. Ltd.

Glaukos

94.64
+4.685.20%
Post-market: 94.640.00000.00%16:39 EDT
Volume:735.28K
Turnover:69.36M
Market Cap:5.41B
PE:-41.72
High:96.21
Open:93.45
Low:93.42
Close:89.96
Loading ...

Stock Track | Glaukos (GKOS) Plummets 13.2% as Wider Q4 Loss Disappoints Investors

Stock Track
·
21 Feb

Stock Track | Glaukos Plunges 11.67% in Pre-market on Wider Q4 Loss

Stock Track
·
21 Feb

BUZZ-Glaukos falls on wider-than-expected Q4 loss

Reuters
·
21 Feb

GKOS Stock Falls Despite Q4 Earnings & Revenue Beat, Margins Decline

Zacks
·
21 Feb

Glaukos Is Maintained at Buy by Needham

Dow Jones
·
21 Feb

S&P 500 Futures Steady In Premarket Trading; Celsius Holdings, MercadoLibre Lead

Dow Jones
·
21 Feb

Glaukos Corp. : Wells Fargo Raises Target Price to $160 From $153

THOMSON REUTERS
·
21 Feb

Analysts Conflicted on These Healthcare Names: Glaukos (GKOS), Danaher (DHR) and Evolent Health (EVH)

TIPRANKS
·
21 Feb

Glaukos: Surpassing Milestones with Robust Growth in Glaucoma Segment and Promising iDose Integration

TIPRANKS
·
21 Feb

Glaukos Corp (GKOS) Q4 2024 Earnings Call Highlights: Record Sales and Strategic Growth Amid ...

GuruFocus.com
·
21 Feb

BUZZ-Glaukos rises after Mizuho upgrades rating to 'outperform'

Reuters
·
19 Feb

Mizuho Upgrades Glaukos Corp to Outperform From Neutral, Adjusts Price Target to $200 From $140

MT Newswires Live
·
19 Feb

What to Expect From These 3 MedTech Stocks This Earnings Season?

Zacks
·
19 Feb

Glaukos Corp : Mizuho Raises Target Price to $200 From $140

THOMSON REUTERS
·
19 Feb

Mizuho upgrades Glaukos to Outperform on ‘bullish’ iDose checks

TIPRANKS
·
19 Feb

Glaukos upgraded to Outperform from Neutral at Mizuho

TIPRANKS
·
19 Feb

What Analyst Projections for Key Metrics Reveal About Glaukos (GKOS) Q4 Earnings

Zacks
·
17 Feb

56% Of This Glaukos Insider's Holdings Were Sold

Simply Wall St.
·
08 Feb

Mesa Labs (MLAB) Q3 Earnings and Revenues Beat Estimates

Zacks
·
04 Feb

Glaukos Price Target Raised to $180.00/Share From $140.00 by Piper Sandler

Dow Jones
·
27 Jan